In a recent study presented at the annual meeting of the American Urological Association, Dr. Jeffrey K. Mullins of the Johns Hopkins Brady Urological Institute in Baltimore concluded that the adoption of robotic technology in organ-confined prostate cancer surgeries has a positive impact on patient morbidity, length of hospital stay, post-surgical hospital readmissions, and overall recovery. Continue Reading
Da Vinci Surgery
The Robot Wins Again Robotic Technology and Prostate Cancer Surgery
Robotic Surgery For Prostate Cancer Gets A Bad Wrap
A new study from Duke University Medical Center, led by Dr. Judd W. Moul, a prostate surgeon, suggests that men’s expectations of laparoscopic robot-assisted prostatectomy may be too high. The study found that of 171 men facing prostate cancer surgery, those having robotic surgery expected a shorter hospital stay and a quicker return to their usual physical activity and sex life. Dr. Moul points out that those hopes may not be realistic. I disagree with this observation. Continue Reading
Robotic Surgery— A Better Mousetrap For The Treatment of Prostate Cancer
Not all patients diagnosed with prostate cancer are candidates for surgical removal of the prostate gland. Those who are will benefit greatly from the da Vinci robot-assisted prostatectomy, now widely performed at most major hospitals throughout the United States. Continue Reading
The Gold Standard: Robotic Surgery for Prostate Cancer Cure
For those men diagnosed with “aggressive”, organ-confined carcinoma of the prostate, and who are candidates for surgery, the robotic-assisted laparoscopic prostatectomy is now the Gold Standard. Continue Reading
Prostate Cancer: The Good News
PROSTATE CANCER: THE GOOD NEWS
This is Prostate Cancer Awareness Month all across America. Prostate cancer is one of the most serious health problems in the United States. It has touched almost everyone by involving either a family member or a friend. More than 240,000 new cases of prostate cancer will be diagnosed in the United States this year. It is the most common male malignancy, and the second most common cause of death from all cancers.




